The increasing complexity of Premarket Approval (PMA) and 510(k) applications over the years is putting a significant strain on the US Food and Drug Administration’s ability to meet its user-fee deadlines, an agency official familiar with the review process said. Without additional funding, the official predicts that the agency may not be able to keep up in coming years.
As the FDA negotiates with industry over the next iteration of the Medical Device User Fee Amendments (MDUFA V), an...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?